BioNTech SE (BNTX)
| Market Cap | 25.64B +3.5% |
| Revenue (ttm) | 3.03B -7.9% |
| Net Income | -1.93B |
| EPS | -7.77 |
| Shares Out | 251.20M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,170,849 |
| Open | 102.34 |
| Previous Close | 111.40 |
| Day's Range | 98.80 - 105.23 |
| 52-Week Range | 79.52 - 124.00 |
| Beta | 1.28 |
| Analysts | Buy |
| Price Target | 120.09 (+17.65%) |
| Earnings Date | Aug 4, 2026 |
About BNTX
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 cli... [Read more]
Financial Performance
In 2025, BioNTech SE's revenue was 2.87 billion, an increase of 4.32% compared to the previous year's 2.75 billion. Losses were -1.14 billion, 70.8% more than in 2024.
Financial numbers in EUR Financial StatementsAnalyst Summary
According to 20 analysts, the average rating for BNTX stock is "Buy." The 12-month stock price target is $120.09, which is an increase of 17.65% from the latest price.
News
BioNTech Stock (BNTX) Is Tumbling on Friday – Here’s Why
BioNTech ($BNTX) shares declined as much as 10% on Friday after the company said it has ended a key Phase 2 trial for its mRNA colorectal cancer vaccine. The study…
Cevumeran trial termination a ‘clear setback’ for BioNTech, says BMO Capital
BMO Capital analyst Evan Seigerman calls BioNTech’s (BNTX) termination of the Phase 2 autogene cevumeran trial in resected colorectal cancer “a clear setback,” noting that the study’s monitoring board...
mRNA immunotherapy discontinuation a negative for BioNTech, says Morgan Stanley
After BioNTech (BNTX) announced the discontinuation of its Phase 2 study partnered with Roche (RHHBY) of autogene cevumeran, an individualized mRNA immunotherapy, or cancer vaccine, in adjuvant colore...
BioNTech to terminate mid-stage trial of mRNA cancer vaccine
BioNTech SE said on Friday it has decided to terminate the mid-stage trial of its experimental mRNA-based cancer vaccine for patients with a type of colorectal cancer, sending the German firm's U.S...
BioNTech drops 9% after ending Phase 2 colorectal cancer trial
Shares of BioNTech (BNTX) trading in New York are down $9.56, or nearly 9%, to $101.84 following the announcement.
BioNTech to terminate Phase 2 monotherapy trial of cevumeran
In a regulatory filing, BioNTech (BNTX) SE disclosed that on August 28 the company announced that it has decided to terminate the Phase 2 clinical trial evaluating autogene cevumeran, an…
US FDA approves updated COVID vaccines for 2026-27 season
The U.S. Food and Drug Administration approved Moderna, Novavax-Sanofi and Pfizer-BioNTech's updated COVID vaccines, the companies said on Thursday, after an advisory panel recommended that the shot...
Pfizer and BioNTech receive FDA approval for XFG-adapted COVID-19 vaccine
Pfizer (PFE) and BioNTech (BNTX) announced that the FDA has approved the supplemental Biologics License Application for the companies’ 2026-2027 COVID-19 vaccine formula targeting the XFG variant, COM...
Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine
NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that the U.S. Food and Drug Administration (FDA) has approved t...
BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026
MAINZ, Germany, August 20, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present new clinical data from its diversified development program in lung cancer treatment at the IASLC ...
BioNTech price target lowered to $130 from $135 at Evercore ISI
Evercore ISI analyst Cory Kasimov lowered the firm’s price target on BioNTech (BNTX) to $130 from $135 and keeps an Outperform rating on the shares.
BioNTech price target raised to $142 from $138 at Canaccord
Canaccord raised the firm’s price target on BioNTech (BNTX) to $142 from $138 and keeps a Buy rating on the shares. The firm noted they lowered their Covid guidance but…
BioNTech price target lowered to $125 from $130 at Citi
Citi lowered the firm’s price target on BioNTech (BNTX) to $125 from $130 and keeps a Buy rating on the shares.
BioNTech SE Earnings Call Transcript: Q2 2026
Q2 2026 saw revenues decline year-over-year due to lower COVID-19 vaccine demand and absence of one-time revenue, while oncology pipeline advanced with multiple pivotal trials and robust clinical data. Revised 2026 guidance reflects weaker vaccine demand, but strong cash reserves and disciplined capital allocation support continued investment in late-stage assets.
BioNTech SE Earnings release: Q2 2026
BioNTech SE released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
BioNTech SE Slides: Q2 2026
BioNTech SE has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.
Why Pfizer Stock and This Covid Vaccine Partner Are Falling on Earnings
Pfizer beats earnings forecasts for the second quarter, while BioNTech's results miss expectations due to weak Covid vaccine demand.
BioNTech lowers 2026 sales outlook as COVID vaccine demand softens
German vaccine maker BioNTech lowered its full year sales outlook range on Tuesday due to softer-than-expected COVID-19 vaccine demand and the timing of milestone-related revenues.
BioNTech cuts FY26 revenue view to EUR 1.6B-EUR 1.9B from EUR 2B-EUR 2.3B
The company said, “BioNTech (BNTX) is revising its full-year 2026 financial guidance revenue range due to: COVID-19 vaccine market. Softer than anticipated global COVID-19 vaccine demand. In Germany e...
BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update
Guido Oelkers, Ph.D., appointed to BioNTech Management Board as Chief Executive Officer , taking office by February 1, 2027, at the latest Advanced diversified pipeline now with 14 ongoing pivotal cli...
BioNTech says Sobi's Oelkers will replace Sahin as CEO
German biotech firm BioNTech said on Monday that Sobi's CEO Guido Oelkers will succeed Ugur Sahin as its chief executive.
BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer
Mainz, Germany, August 3, 2026 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that its Supervisory Board has appointed Guido Oelkers, Ph.D., to the Manageme...
European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union
NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that the European Commission (EC) has granted marketing authori...